At myotwin, we developed a human heart organoid from stem cells to deliver accurate and reliable data for your drug testing and preclinical research needs. Our unique measurement platform combines electrophysiology, calcium oscillation, and contractility read outs, providing human-relevant results that reduce the risk of costly failures in clinical trials. In order to enhance your cardiovascular drug development pipeline, we developed the first technology that also measures passive contraction forces. This gives the opportunity to not only run toxicology assays, but also efficacy studies on distinct disease models such as fibrosis, inflammation, and heart attack. We can also run studies on biodistribution or analyse cell line qualities.

Our long-term vision is to utilise our measurement technology to build the best-in-class digital twin of the human heart for AI-based drug repurposing activities, structure activity predictions, or toxicology & efficacy predictions.